HEALTH

The Female Health Company and Aspen Park Pharmaceuticals names board of combined company

BY Michael Johnsen

CHICAGO  – The Female Health Company and Aspen Park Pharmaceuticals on Thursday named the members of the new board of directors of the combined company who will begin serving upon completion of their proposed merger.
“The Veru Healthcare Board includes some of the most highly regarded and renowned individuals in their respective fields,” stated O.B. Parrish, chairman and CEO FHC.

“This board brings the right blend of commercial, medical, pharmaceutical and financial expertise and experience to help guide management in the operation of Veru Healthcare, a diversified pharmaceutical and consumer health men’s and women’s health and oncology company,” added Elgar Peerschke APP board member and chairman of the new board.

“Since the transaction was announced in April, the management teams of both companies have been working closely to ensure a seamless integration. As part of that effort, we formed a transition team that is focusing considerable attention on advancing APP’s product pipeline and further developing the strategic plan to expand the commercial markets for FC2 in the U.S. and internationally,” noted Mitchell Steiner, CEO APP and Veru Healthcare.

The board of the combined company, to be called Veru Healthcare, will be comprised of nine members, with three directors named by FHC (Parrish, David Bethune and Mary Margaret Frank), three directors currently on APP’s Board of Directors (Steiner, Harry Fisch and Peerschke) and three new directors (Georges Makhoul, Lucy Lu and Mario Eisenberger).

Veru Healthcare's board of directors:

  • Elgar Peerschke, chairman. Peerschke is president advisory services at Quintiles Transnational Holdings and was previously senior partner in the Global Health Care Practice of Bain and Company;
  • Mitchell Steiner, vice chairman, CEO and president. Steiner is co-founder, CEO and president of APP, and was previously president, urology of OPKO Health. Steiner is a board certified urologist and was professor and chairman of urology, University of Tennessee;
  • David Bethune, director. Bethune has served as a Director of FHC since 1996 and was previously chairman and CEO of Zila. He has served as founding trustee of the American Cancer Society Foundation and founding chairman of the Corporate Council of the New York City Children’s Health Fund;
  • Mario Eisenberger, director. Eisenberger is professor of oncology at Johns Hopkins University, and was previously head of Advanced Prostate Cancer Committee of Southwest Oncology Group. Eisenberger has served on advisory boards for Bristol Myers Squibb, Sanofi, Jansen, Ipsen, Medivation, Astellas, Ortho Biotech, Bayer and others and as an Ad Hoc member of the Oncologic Drugs Advisory Committee of the FDA. He is a founder of Oncology Insights, aclinical trials contract research organization;
  • Harry Fisch, director and COO. Fisch is a co-founder and chairman of APP, and was previously clinical professor of urology and reproductive medicine at Cornell University. He is a board certified urologist and author;
  • Mary Margaret Frank, director. Frank has served as a director of FHC since 2004 and is associate professor of accounting at the Darden Graduate School of Business at the University of Virginia and Academic Director for Darden’s Initiative for Business in Society and was previously assistant professor at the University of Chicago Booth School of Business. She has a master’s degree and Ph.D. in accounting from the University of North Carolina at Chapel Hill, and has been a CPA since 1994;
  • Lucy Lu, director. Lu is Interim president and CEO of Avenue Therapeutics and EVP and CFO of Fortress Biotech, and was previously senior biotechnology equity analyst with Citigroup Investment Research and Principal of First Albany Capital;
  • Georges Makhoul, director. Makhoul is CEO of Constellation Holdings and was previously president of Morgan Stanley Investment Banking Europe, Middle East and North Africa; and led National Science Foundation Research Center at Columbia University; and
  • O.B. Parrish, director. Parrish is co-founder, chairman and CEO of The Female Health Company and was previously president of Searle's Global Pharmaceutical Group and EVP of Pfizer International division.
     

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Performance Health launches Biofreeze into retail from professional market

BY Michael Johnsen

AKRON, Ohio – Performance Health recently announced the availability of Biofreeze at consumer retail starting in the fall of 2016.

For 25 years, in concert with healthcare professionals, Biofreeze Pain Reliever has been helping people reduce their pain. Now the brand will also reach consumers who purchase pain relief products at retail, including grocery, drug and mass merchandise stores, expanding the reach of the pain relief that Biofreeze and its healthcare professional partners provide.

“Pain is a limiting factor in many people’s lives. When you are in pain and missing the best parts of life, you appreciate finding a new product or a new expert to help you get back to it," stated Ethan Pochman, VP global marketing Performance Health. "Our expansion into retail will expose more people to the power of both Biofreeze and our partners, this country’s talented pain relief professionals,” he said. “The success of Biofreeze and its army of supporters rally around one simple fact: it’s proven to work. In addition to being the No. 1 recommended brand of pain relief professionals, Biofreeze is also the No. 1 topical pain reliever recommended by retail pharmacists, and the topical pain relief brand most searched for on the Internet. That speaks to 25 years of pain relief that really works.”

Biofreeze Pain Reliever is a safe and effective pain relief alternative because it is non-systemic, non-narcotic and contains no NSAIDs, salicylates or addictive substances. It does not require a prescription, contains United States Pharmacopeia grade menthol to provide fast acting pain relief and is free of parabens and propylene glycol.

Biofreeze is available in both its signature green and colorless (dye-free) formats, is never tested on animals and is produced in the United States.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Nature’s Bounty teams with Olympic great Mary Lou Retton

BY Michael Johnsen

RONKONKOMA, N.Y. – Nature's Bounty on Tuesday announced it is teaming up with decorated gymnast Mary Lou Retton on the #DearFutureMe campaign to help catapult attention for the importance of thinking about future health today. As a notable five-time medalist, Mary Lou Retton is reflecting on her personal health goals and experiences to inspire others to pay it forward when it comes to their own future health.   

"Nature's Bounty and legendary athlete Mary Lou Retton have partnered on the #DearFutureMe campaign to help flip the health conversation from short-term goals toward enjoying a long, active healthy lifestyle in the future," said Chris O'Connor, VP Nature's Bounty.  "Bar none, Mary Lou personifies the commitment to health and wellness that has been at the core of Nature's Bounty's trusted experience for nearly 50 years."

"As a competitive athlete and mom, I know how important it is to maintain a healthy life and work hard to keep the future health of my family and me a priority even in the midst of hectic schedules attending gymnastic meets for each of our four daughters," said Mary Lou Retton. "Through the #DearFutureMe campaign, I hope to encourage others to think about their mental, emotional, social and physical wellbeing and take realistic steps today towards achieving that healthy tomorrow."
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?